Improving Outcomes in Aortic Dissection: Upfront TEVAR vs Surveillance (IMPROVE-AD) for Uncomplicated Type B Dissection
Official title: 1/2 IMPRoving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
Funded at Duke University · NIH-11605967 · Data updated 2026-11-12
A large, patient-friendly study will compare starting with medicine plus an upfront TEVAR procedure versus medicine with careful monitoring for people with uncomplicated type B aortic dissection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project start | July 21, 2023 |
| Project end | June 30, 2030 |
| Funding year | 2026 |
| Award (this year) | $4,260 |
| NIH project number | 3UH3HL165017-04S1 |
| Project ID | NIH-11605967 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with uncomplicated type B aortic dissection who meet trial eligibility.
✕Less likely to help
Patients with contraindications to TEVAR or who do not fit the study criteria may not benefit.
What this research studies
This project plans a pragmatic, multicenter trial in the United States enrolling about 1,100 participants to determine whether adding upfront TEVAR to standard medical therapy improves outcomes compared with ongoing medical therapy and monitoring in uncomplicated type B aortic dissection. Participants will undergo routine medical care with assessments for signs of deterioration, and clinically indicated TEVAR or open repair may be performed if needed. The trial is led by Duke, Baylor, and University of Washington teams with a dedicated data and clinical coordination center to ensure robust and real-world applicability. The aim is to establish clear guidance on how best to manage uTBAD to reduce death and complications.
Why it matters
Potential benefit: If successful, the trial could change standard care for uTBAD, potentially improving survival and reducing complications.
How similar studies have gone: This is one of the first large-scale trials to evaluate upfront TEVAR in uTBAD, with the potential for impactful results.
Where this research is happening
-
Duke University
Durham, United States Active
Researchers
- Principal investigator: Patel, Manesh R — Duke University
- Study coordinator: Patel, Manesh R
Related research
Other NIH-funded projects on the same topics.
-
Improving Outcomes in Vascular Disease for Aortic Dissection: Upfront TEVAR vs Surveillance
A large US study will compare starting treatment with a repair procedure plus medicine to medicine alone with careful follow-up in people with uncomplicated type B aortic dissection.
-
IMPROVE-AD: Better outcomes for uncomplicated type B aortic dissection
A large patient study in the US will compare starting with medical care plus upfront TEVAR versus medical care with monitoring alone to see which approach leads to better outcomes for people with uncomplicated type B aortic dissection.
-
Upfront TEVAR plus medical therapy vs lifelong monitoring for uncomplicated type B aortic dissection
A large US study tests whether adding early TEVAR to standard medical care helps people with uncomplicated type B aortic dissection live better than medical care alone with ongoing monitoring.
-
Non-invasive 4D flow MRI to predict risk in aortic dissection
A study using 4D flow MRI to help doctors predict which patients with aortic dissection are at higher long-term risk so they can tailor treatment.
-
Early aortic stent plus medicine versus medicine with watchful waiting for uncomplicated type B aortic dissection
This compares giving an early aortic stent graft plus medicines to using medicines with close follow-up for people with uncomplicated type B aortic dissection to find which approach leads to better outcomes.
-
Improving care for people with type B aortic dissection
This study will compare immediate stent-graft repair plus medicines to medicines with watchful waiting for people with uncomplicated type B aortic dissection.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.